Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number.

OIVIB CO	Substitute for form	1449/PTO		Complete if Known	OPA	
	INFORMATION DIS	SCLOSURE	Application Number	09/622,646		\mathcal{T}
	STATEMENT BY		Filing Date	2/25/1999	- MAD D	3
	Data Culturalities de Ma	00 0044	First Named Inventor	Yasuko OZAKI	MAR 2 8 2011	<u>il</u>
	Date Submitted: Ma	Irch 20, 2011	Art Unit	1641	图 4	<u>"</u>
•	(use as many sheets	as necessary)	Examiner Name	Christine E. FOS		<u> </u>
Sheet	1 0	f 1	Attorney Docket Number	053466-0286	MADEMARKO	

U.S. PATENT DOCUMENTS					
Examin er	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.'	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Figures Appear
	ļ				

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	F1	Gerd ZETTLMEISSL, et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins", DNA AND CELL BIOLOGY, 1990, Volume 9, Number 5, pages 347-353	
	F2	Shuji OZAKI, et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Blacka Coll Spacific Antigan, HMI 24" RLOOD, October 15, 1997, Volume 90, Number 8, pages 3179-	
		3186	
	F3	Shuji OZAKI, et al., "Preferential Expression of Human \(\lambda \)-Light-Chain Variable-Region Subgroups in Multiple Myelome, AL Amyloidosis, and Waldenström's Macroglobulinemia", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, May 1994, Volume 71, Number 2, pages 183-189	
	F4	Tetsuva GOTO, et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated	
		Human B Cells", BLOOD, September 15, 1994, Volume 84, Number 6, pages 1922-1930	

Examiner Signature	/Christine Foster/ (03/30/2011)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: